Business Context and Reporting Period
Cytosorbents Corp (Cytosorbents) filed an 8-K Current Report on March 29, 2018, regarding the entry into a material definitive agreement. The filing details a refinancing transaction with Bridge Bank, a division of Western Alliance Bank, involving the Company and its wholly-owned subsidiary, CytoSorbents Medical, Inc.
Key Financial Metrics and Debt Structure
The filing discloses the terms of a new credit facility rather than historical financial performance metrics such as revenue or profit.
- Total Credit Facility: Up to $15 million in aggregate Term Loans.
- Tranche A (Term A Loan): $10 million funded immediately on the Closing Date to refinance prior indebtedness.
- Tranche B (Term B Loan): $5 million available at the Borrower's request prior to March 31, 2019, subject to conditions.
- Interest Rate: Floating per annum rate based on the Effective Interest Rate defined in the agreement.
- Repayment Terms: Monthly interest payments commence the month after funding. Principal amortization begins November 1, 2019 (or May 1, 2020 if Term B is funded). Full maturity is April 1, 2022.
- Closing Fees: Non-refundable closing fee of $25,000.
- Final Fee: 2.5% of the principal amount of each funded Term Loan, payable at maturity or upon prepayment/acceleration.
- Prepayment Penalties: 2.0% if prepaid within the first year; 1.5% in the second year; 1.0% thereafter through March 31, 2022.
Material Changes and Success Fee Provisions
The Company amended and restated its prior Loan and Security Agreement dated June 30, 2016. A significant material change is the inclusion of a Success Fee Letter contingent upon the funding of the Term B Loan.
- Success Fee Trigger: If Term B is drawn, a success fee equal to 6.37% of the funded amount is triggered upon a "Liquidity Event."
- Liquidity Events: Includes asset sales, mergers, change of control, or if the stock price exceeds specific thresholds (e.g., 70% above $7.05 for five successive days).
- Payment Method: Payable in cash or, at the Company's election for stock-price triggers, via issuance of common stock.
- Expiration: The Success Fee obligation terminates on the fifth anniversary of the Term B funding date.
Guidance, Risks, and Contingencies
The filing does not provide forward-looking revenue guidance or management commentary on operational outlook. However, it outlines specific risks and contingencies associated with the debt agreement:
- Collateral: Obligations are secured by a first-priority security interest in the Borrower's shares and collateral, excluding intellectual property.
- Events of Default: Include non-payment, failure to perform covenants, Material Adverse Events, seizure of assets, or insolvency proceedings.
- Use of Proceeds: Funds are designated for working capital and general business requirements.
Investor Verification Checklist
- Verify the exact "Effective Interest Rate" formula defined in the attached Restated Loan and Security Agreement (Exhibit 10.1).
- Confirm the specific conditions precedent required to draw the $5 million Term B Loan.
- Review the definition of "Material Adverse Event" within the agreement to understand default triggers.
- Assess the potential dilution impact if the Success Fee is triggered via stock issuance rather than cash payment.
- Check the status of the prior indebtedness refinanced by the $10 million Term A Loan to ensure full payoff.